AML-437 Real-World Effectiveness of Enasidenib (ENA) in Older Patients With Relapsed/Refractory (R/R) Isocitrate Dehydrogenase-2 (IDH2)-Mutated Acute Myeloid Leukemia (AML)

Autor: McBride, Ali 1, Klink, Andrew J. 2, Ullman, Amanda J. 1, Liassou, Djibril 2, Brown-Bickerstaff, Cherrishe 2, Gajra, Ajeet 2
Zdroj: In Clinical Lymphoma, Myeloma and Leukemia October 2022 22 Supplement 2:S250-S251
Databáze: ScienceDirect